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ABSTRACT

Provided are methods and compositions for the treatment or

prevention of ocular angiogenesis and neovasculariZation.
Administration of inhibitors of the CCR3 receptor or its

ligands eotaxin (CCL11), eotaxin-2 (CCL24) or eotaxin-3

(CCL26) inhibits ocular angiogenesis.
9 Claims, 11 Drawing Sheets
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CCR3 INHIBITION FOR OCULAR
ANGIOGENESIS AND MACULAR
DEGENERATION

comprises administering an effective amount of a CCR3

speci?c binding molecule to a patient having, or at risk for
having, choroidal neovasculariZation or Wet macular degen
eration.
The invention also relates to a method for screening for a

CROSS-REFERENCE TO RELATED
APPLICATION

compound that interacts With CCR3. In one aspect, the

method comprises contacting CCR3 polypeptide or binding
fragment thereof With a test compound, and determining if a

This application is a divisional of US. application Ser. No.
12/247,722 ?led Oct. 8, 2008 Which claims priority to US.

Application No. 60/998,348, ?led Oct. 9, 2007, the entire
disclosures of Which are expressly incorporated by reference

10

complex is formed betWeen CCR3 polypeptide or binding
fragment thereof and the test compound. In another aspect,
the test compound identi?ed as interacting With CCR3 is

assayed for the ability to inhibit ocular angiogenesis.
Other systems, methods, features and advantages of the

herein.

present invention Will be or become apparent to one With skill

FIELD OF THE INVENTION

in the art upon examination of the folloWing draWings and
detailed description. It is intended that all such additional

The present invention relates to the suppression of ocular

systems, methods, features and advantages be included

angiogenesis by inhibiting the CCR3 receptor.

Within this description, be Within the scope of the present

invention, and be protected by the accompanying claims.

DESCRIPTION OF THE RELATED ART
20

The macula is the part of the retina Which is responsible for
central vision. Age-related macular degeneration is a chronic

BRIEF DESCRIPTION OF THE DRAWINGS

eye disease that occurs When tissue in the macula deteriorates.

FIG. 1 illustrates the effect of laser injury on the number of
CCR3 receptors on choroidal endothelial cells.

Macular affects central vision, but not peripheral vision.
Macular degeneration is the leading cause of severe vision
loss in people age 60 and older.
There are tWo forms of age-related macular degeneration:
dry and Wet. Dry macular degeneration is the most common
type of macular degeneration and occurs When cells of the

25

macula sloWly begin to break doWn. YelloW deposits called
“drusen” form under the retina betWeen the retinal pigmented

30

FIG. 2 shoWs the effect of CCR3 antibody on the prolif

eration of choroidal endothelial cells folloWing laser injury.
FIG. 3 illustrates the dose-dependent effect of CCR3 anti
body on choroidal neovasculariZation volume
FIG. 4 shoWs lack of in?ltration of eosinophils and mast

cells into the choroid folloWing laser injury.
FIG. 5 illustrates the lack of change of number of in?ltrat

epithelium (RPE) and Bruch’s membrane, Which supports the

ing macrophages in the choroid following laser injury and

retina. The drusen deposits are debris associated With com

CCR3 antibody treatment.
FIG. 6 shoWs the effect of laser injury on the number of
CCR3 receptors in vivo on proliferating and quiescent mouse
choroidal endothelial cells.
FIG. 7 illustrates the dose-dependent reduction in CNV
volume caused by the CCR3 small molecule antagonist

promised cell metabolism in the RPE. Eventually there is a
deterioration of the macular regions associated With the
drusen deposits resulting in a loss of central vision.

35

Wet macular degeneration occurs When abnormal bold ves
sels groW behind the macula. These vessels are fragile and can

leak ?uid and blood, Which result in scarring of the macula
and raise the potential for rapid, severe damage. Bruch’s
membrane breaks doWn, usually near drusen deposits. This is

SB328437 ((S)-methyl-2-naphthoylamino-3-(4-nitrophenyl)
40

propionate.
FIGS. 8(A), 8(B) and 8(C) present immunohistochemical

Where neW blood vessel groWth, or neovasculariZation,

analysis of the expression of CCR3 in the retina and choroid

occurs. Central vision can become distorted or lost entirely in

of normal patients and patients With age-related macular

a shore period of time, sometimes Within days. Wet macular
degeneration is responsible for about 10 percent of the cases
of age-related macular degeneration, but it accounts for about
90 percent of the cases of legal blindness.

degeneration.
45

SUMMARY OF THE INVENTION
50

FIG. 9 a graph of the CEC F-actin polymerization after
eotaxin stimulation. PolymeriZation peaked at 10 seconds
after stimulation With all eotaxins (eotaxin-1>eotaxin-3>eo
taxin-2). Eotaxin-1 and -3 also induced a second delayed
burst of F-actin polymeriZation betWeen 30 and 60 seconds.
PBS controls resulted in no signi?cant increase in F-actin

polymeriZation from baseline.
FIG. 10A presents ?uorescent microscopic images seen

In one aspect, the present invention relates to a method of

inhibiting ocular angiogenesis. The method comprises expos
ing a retinal or choroidal cell to a CCR3-inhibitory effective

from the ?uorescent baseplate assay. FIG. 10A shoWs the

amount of a compound Which inhibits the activity of CCR3.
The present invention also relates to a composition for the
inhibition of ocular angiogenesis. The composition com

untreated baseline cultures. Minimal ?uorescence Was seen in
55

prises a compound Which inhibits the activity of CCR3.
In another aspect, the present invention relates to a method
of diagnosing or monitoring choroidal neovasculariZation or

Wet macular degeneration. The method comprises adminis
tering a labeled CCR3-speci?c binding molecule to a patient

60

and detecting the presence or absence of the labeled molecule
in the retina or choroid of the patient, the presence of the

labeled molecule being indicative of choroidal neovascular
iZation or Wet macular degeneration. In still another aspect,
the present invention relates to a method of treating choroidal
neovasculariZation or Wet macular degeneration. The method

65

the untreated baseline cultures Which Were approximately
70-80% con?uent.
FIG. 10B shoWs assay results With eotaxin 1.
FIG. 10C shoWs assay results With eotaxin 2.
FIG. 10D shoWs assay results With eotaxin 3. After 10
seconds of eotaxin stimulation, hCEC cultures exhibited
increased ?uorescence and cord formation characteristic of
F-actin polymerization. Scale bars 50 um.
FIG. 11 presents a Rac-1 activation assay. FIG. 11A shoWs
that eotaxins activate Rac-1 GTPase in Human CECs
(hCECs). hCECs) Were stimulated With Eotaxin- 1, 2 and 3 for
the indicated times. Cells Without Eotaxin stimulation Were
used as a control (0 sec). FIG. 11B shoWs a graph of the levels

US 8,592,482 B2
3

4

of increase of active Rac-1, measured after normalizing
against the control band density. Eotaxin-1 stimulation
seconds (diamonds). Eotaxin-2 and Eotaxin-3 stimulation

described in U.S. Pat. No. 6,984,643; piperiZinones such as
those described in U.S. Pat. No. 6,974,869; bicycylic and
tricyclic amines such as those described in U.S. Pat. No.
6,960,666; N-ureidoalkyl-piperidines such as those

shoWed 3 to 5 fold increase of Rac-1 activation peaking at 60

described in U.S. Pat. Nos. 6,949,546, 6,919,368, 6,906,066,

seconds (squares and triangles respectively).

6,897,234, 6,875,776, 6,780,857, 6,627,629, 6,521,592 and

showed about 6.5 fold increase of Rac-1 activation at 10

6,331,541; bicyclic diamines such as those described in U.S.
Pat. No. 6,821,964; benZylcycloalkyl amines such as those
described in U.S. Pat. No. 6,864,380; 2-substituted-4-nitro
gen heterocycles such as those described in U.S. Pat. No.

DETAILED DESCRIPTION

Intraocular in?ammation is not clinically apparent in age
related macular degeneration. HoWever, there is evidence

6,706,735; ureido derivatives of poly-4-amino-2-carboxy-1

methyl pyrrole compounds; bicyclic and bridged nitrogen

suggesting an in?uential role for in?ammation in this condi
tion. CCR3 is a promiscuous chemokine receptor that is pre

heterocycles such as those described in U.S. published appli

dominantly expressed by eosinophils but also is found on

cation 20050234034; aZetidine derivatives such as those

other leukocytes and some endothelial and epithelial cells.
The invention relates to methods and compositions for the

described in U.S. published application 20050222118; sub

treatment or prevention of ocular angiogenesis and neovas
culariZation. Administration of inhibitors of the CCR3 recep

published application 20050197373; substituted spiro aZabi

tor or its ligands, for example eotaxin (CCL11), eotaxin-2
(CCL24) or eotaxin-3 (CCL26), inhibits ocular angiogenesis.

stituted fused bicyclic amines such as those described in U.S.

cyclics such as those described in U.S. published application
20050197325; piperidine-substituted indoles or hetero
20

derivatives thereof such as those described in U.S. published

Ocular angiogenesis includes choroidal angiogenesis and
retinal angiogenesis. Compositions and methods for inhibit

application 20050153979; piperidinyl and piperaZinyl com
pounds substituted With bicyclo-heterocyclylalkyl groups

ing CCR3, eotaxin (CCL11), eotaxin-2 (CCL24), and

such as those described in U.S. published application
20050090504; arylsulfonamide derivatives such as those

eotaxin-3 (CCL26) for the treatment and/or prevention of
neovascular disease are provided. Also provided are novel

25

described in U.S. published application 20050070582;

therapeutic targets and diagnostic markers for choroidal

1-phenyl-1,2-diaminoethane derivatives

neovasculariZation.

described in U.S. published application 20040063779; (N-{

Any compound Which inhibits the activity of CCR3 may be
used in the present invention. Such compounds include
inhibitory molecules Which bind directly to the CCR3 recep

methyl-2H-tetraaZol-5-yl)methyl]urea) (see, e. g., Nakamura

such as those

[2S]-4-(3,4-dichlorobenZyl)morpholin-2-yl}methyl)-N'[(2

30

tor, antibodies Which bind the CCR3 receptor or to the natural

et al., Immunol Res., 33:213-222, 2006; N-{(3R)-1-[(6
?uoro-2-naphthyl)methyl]pyrrolidin-3 -yl} -2-{ 1 -[(3 -me

ligands of the CCR3 receptor, including eotaxin (CCL11),

thyl-1-oxidopyridin-2-yl)carbonyl]piperidin-4

eotaxin-2 (CCL24) and eotaxin-3 (CCL26), RNA, DNA or

ylidene}acetamide (see, e.g., Suzuki et al., Biochem.

RNA/DNA aptamers Which speci?cally bind CCR3, eotaxin,
eotaxin-2 or eotaxin-3, and siRNA or anti-sense oligonucle

Biophys. Res. Commun., 339:1217-1223, 2006; N-{(3R)-1

35

otides Which inhibit the expression of CCR3, eotaxin,

ylidene}acetamide hemifumarate (see, e.g., Morokata et al.,
J. Pharmacol. Exp. Ther., Dec. 9, 2005 [Epub ahead of print]);

eotaxin-2 or eotaxin-3. Additional compounds Which inhibit

the activity of CCR3 include inhibitory molecules Which
speci?cally bind CCR3, eotaxin, eotaxin-2 or eotaxin-3,

including an oligopeptide, small molecule antagonist (e.g.,
organic molecule having a molecular Weight less than 2000,

bipiperidine amide antagonists of CCR3 such as those
40

or less than 1000, or less than 500), riboZyme, intrabody or

intraceptor. An intrabody refers to an antibody produced
intracellularly, for example, a single chain antibody (such as
a single chain Fv antibody fragment) expressed inside a cell

45

transformed With an appropriate exogenous nucleic acid. An
intraceptor refers to an receptor (such as a receptor for CCR3,

described in Ting et al., Bioorg. Med. Chem. Lett., 15:3020

3023 -2005; (S) -methyl-2-naphthoylamino -3 -(4-nitrophenyl)
propionate (see, e.g., Beasley et al., J. Allergy Clin. Immu
nol., 105: S466-S472, 2000; and the CCR3 antagonist
compounds described in Fryer et al., J. Clin. Invest., 116:228
236, 2006.
Additional compounds for inhibiting the CCR3 receptor
include RNA, DNA or RNA/DNA aptamers directed against
CCR3, eotaxin, eotaxin-2 or eotaxin-3. Exemplary methods
for making aptamers are described in U.S. Pat. Nos. 5,270,

eotaxin, eotaxin-2 or eotaxin-3) produced intracellularly, for
example, a CCR3, eotaxin, eotaxin-2 or eotaxin-3 receptor
expressed inside a cell transformed With an appropriate exog

[(6-?uoro-2-naphthyl)methyl]pyrrolidin-3 -yl}-2-{1-[(5 -hy
droxy-3-methylpyridin-2-yl)carbonyl]piperidin-4

50

enous nucleic acid.

Numerous “small molecule” inhibitors for the CCR3
receptor have been developed and can be used in the present

163, 5,840,867, 6,180,348 and 6,699,843.
Additional compounds for inhibiting the CCR3 receptor
include anti-sense oligonucleotides or siRNAs directed

against CCR3, eotaxin, eotaxin-2 or eotaxin-3, including the
anti-sense oligonucleotides directed against the CCR3 recep

invention. In one aspect the CCR3 inhibitor is an organic

molecule having a molecular Weight less than 2000. In
another aspect of the invention, the CCR3 inhibitor is an
organic molecule having a molecular Weight less than 1000.
In yet another aspect of the invention, the CCR3 inhibitor is
an organic molecule having a molecular Weight less than 500.

55

The CCR3 receptor inhibitors include piperidine derivatives,
piperidine amides and biperidine compounds such as those

60

tor such as that described in U.S. Pat. No. 6,822,087.
The siRNAs for use in the present invention are designed

according to standard methods in the ?eld of RNA interfer
ence. Introduction of siRNAs into cells may be by transfec

tion With expression vectors, by transfection With synthetic
dsRNA, or by any other appropriate method. Transfection
With expression vectors is preferred.

described in U.S. Pat. Nos. 6,984,651 and 6,903,115, and

The expression vectors Which can be used to deliver siRNA

U.S. published applications 20050176708, 20050182094 and
20050182095; heterocyclic piperidines such as those

according to the invention include retroviral, adenoviral and

described in U.S. Pat. No. 6,759,411; diphenyl-piperidine
derivatives such as those described in U.S. Pat. No. 6,566,

376; 2,5-substituted pyrimidine derivatives such as those

lentiviral vectors. The expression vector includes a sequence
65

Which codes for a portion of the target gene (e.g., CCR3
receptor, eotaxin, eotaxin-2 or eotaxin-3) Which is to be
silenced. The target gene sequence is designed such that,

US 8,592,482 B2
5
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upon transcription in the transfected host, the target RNA

conditions, and cloned by limiting dilution. Cells Which pro

sequence forms a hairpin structure due to the presence of

duce antibodies With the desired speci?city are selected by a

self-complementary bases. Processing Within the cell

suitable assay (e.g., ELISA).
Single chain antibodies, and chimeric, humanized or, pri

removes the loop resulting in formation of a siRNA duplex.
The double stranded RNA sequence should be less than 30
nucleotide bases; preferably the dsRNA sequence is 19-25
bases in length; more preferably the dsRNA sequence is 20

matized (CDR-grafted) antibodies, as Well as chimeric or

CDR-grafted single chain antibodies, comprising portions
derived from different species, are also encompassed by the
present invention and the term “antibody”. The various por

nucleotides in length.
The expression vectors may include one or more promoter

tions of these antibodies can be joined together chemically by

regions to enhance synthesis of the target gene sequence.

conventional techniques, or can be prepared as a contiguous

Promoters Which can be used include CMV promoter, SV40
promoter, promoter of mouse U6 gene, and promoter of
human H1 gene.

protein using genetic engineering techniques. For example,
nucleic acids encoding a chimeric or humanized chain can be

expressed to produce a contiguous protein. See, e.g., Cabilly

One or more selection markers may be included to facili

tate transfection With the expression vector. The selection
marker may be included Within the expression vector, or may
be introduced on a separate genetic element. For example, the

bacterial hygromycin B phosphotransferase gene may be
used as a selection marker, With cells being groWn in the
presence of hygromycin to select for those cells transfected
With the aforementioned gene.
Synthetic dsRNA may also be introduced into cells to

provide gene silencing by siRNA. The synthetic dsRNAs are
less than 30 base pairs in length. Preferably the synthetic
dsRNAs are 19-25 base pairs in length. More preferably the

20

et al., BioTechnology, 10: 1455-1460 (1992), regarding pri
matized antibody, and Ladner et al., US. Pat. No. 4,946,778

25

dsRNAs are 19, 20 or 21 base pairs in length, optionally With
2-nucleotide 3' overhangs. The 3' overhangs are preferably
TT residues.
Synthetic dsRNAs can be introduced into cells by injec

tion, by complexing With agents such as cationic lipids, by use

and Bird, R. E. et al., Science, 242: 423-426 (1 988)) regarding
single chain antibodies.
In addition, functional fragments of antibodies, including
fragments of chimeric, humanized, primatized or single chain
antibodies, can also be produced. Functional fragments of
foregoing antibodies retain at least one binding function and/
or modulation function of the full-length antibody from

30

of a gene gun, or by any other appropriate method.

Additional compounds for inhibiting the CCR3 receptor
include antibodies Which speci?cally bind the CCR3 recep
tor, eotaxin, eotaxin-2 or eotaxin-3. Exemplary antibodies
Which speci?cally bind and inhibit the CCR3 receptor are
described in US. Pat. Nos. 6,806,061 and 6,207,155, and in

et al., US. Pat. No. 4,816,567; Cabilly et al., European Patent
No. 0,125,023. B1; Boss et al., US. Pat. No. 4,816,397; Boss
et al., European Patent No. 0,120,694 B1; Neuberger, M. S. et
al., WO 86/01533; Neuberger, M. S. et al., European Patent
No. 0,194,276 B1; Winter, US. Pat. No. 5,225,539; and Win
ter, European Patent No. 0,239,400 B1. See also, NeWman, R.

Which they are derived. For example, antibody fragments
capable of binding to a mammalian CCR3 receptor, eotaxin,
eotaxin-2 or eotaxin-3 or portion thereof, including, but not
limited to, Fv, Fab, Fab' and F(ab').sub.2 fragments are
encompassed by the invention. Such fragments can be pro

35

duced by enzymatic cleavage or by recombinant techniques.
For instance, papain or pepsin cleavage can generate Fab or

F(ab').sub.2 fragments, respectively. Alternatively, antibodies

US. published applications 20050191702, 20050069955,
and 20020147312. Exemplary antibodies Which speci?cally

can be produced in a variety of truncated forms using anti

bind and inhibit eotaxin and eotaxin-2 are described in US.

body genes in Which one or more stop codons has been

Pat. Nos. 6,946,546 and 6,635,251, and in US. published
applications 20040191255 and 20040014132.
The antibodies of the present invention can be polyclonal

40

chimeric gene encoding a F(ab').sub.2 heavy chain portion
can be designed to include DNA sequences encoding the

CH.sub.1 domain and hinge region of the heavy chain.

or monoclonal, and the term antibody is intended to encom

pass both polyclonal and monoclonal antibodies. Antibodies
of the present invention can be raised against an appropriate

45

immunogen, including proteins or polypeptides of the present

The antibodies of the present invention can be used to
modulate receptor or ligand function in research and thera
peutic applications. For instance, antibodies can act as inhibi

tors to inhibit (reduce or prevent) (a) binding (e.g., of a ligand,

invention, such as isolated and/or recombinant mammalian
CCR3 receptor, eotaxin, eotaxin-2 or eotaxin-3 protein or

a second inhibitor or a promoter) to the receptor, (b) a receptor

signalling, (c) and/or a stimulatory function. Antibodies

portion thereof, or synthetic molecules, such as synthetic

peptides.

introduced upstream of the natural stop site. For example, a

50

Which act as inhibitors of receptor function can block ligand

Preparation of immunizing antigen, and polyclonal and

or promoter binding directly or indirectly (e.g., by causing a

monoclonal antibody production can be performed using any
suitable technique. A variety of methods have been described
(see e.g., Kohler et al., Nature, 256: 495-497 (1975) and Eur.

conformational change). For example, antibodies can inhibit

J. Immunol. 6: 511-519 (1976); Milstein et al., Nature 266:

receptor function by inhibiting binding of a ligand, or by
desensitization (With or Without inhibition of binding of a
55

ligand).
Anti-idiotypic antibodies. are also provided. Anti-idio

550-552 (1977); KoproWski et al., US. Pat. No. 4,172,124;
HarloW, E. and D. Lane, 1988, Antibodies: A Laboratory

typic antibodies recognize antigenic determinants associated

Manual, (Cold Spring Harbor Laboratory: Cold Spring Har

With the antigen-binding site of another antibody. Anti-idio
typic antibodies can be prepared against a second antibody by

bor, N.Y.); Current Protocols In Molecular Biology, Vol. 2
(Supplement 27, Summer ’94), Ausubel, F. M. et al., Eds.,

60

(John Wiley & Sons: NeW York, NY), Chapter 11, (1991)).

immunizing an animal of the same species, and preferably of
the same strain, as the animal used to produce the second

Generally, a hybridoma is produced by fusing a suitable

antibody. See e.g., US. Pat. No. 4,699,880. Single chain, and

immortal cell line (e.g., a myeloma cell line such as SP2/0)

chimeric, humanized or primatized (CDR-grafted), as Well as

With antibody producing cells. The antibody producing cell,
preferably those of the spleen or lymph nodes, are obtained
from animals immunized With the antigen of interest. The
fused cells (hybridomas) are isolated using selective culture

chimeric or CDR-grafted single chain anti-idiotypic antibod
65

ies can be prepared, and are encompassed by the term anti

idiotypic antibody. Antibody fragments of such antibodies
can also be prepared.
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Modulation of mammalian CCR3 receptor function
according to the present invention, through the inhibition of at

amount su?icient for inhibition of a CCR3 receptor function,

and thereby inhibition of ocular angiogenesis.

least one function characteristic of a mammalian CCR3

A variety of routes of administration are possible includ

receptor, provides an effective and selective Way of inhibiting

ing, but not necessarily limited to oral, dietary, topical (e.g.,
eye drops), parenteral (e.g., intravenous, intraarterial, intra
muscular, subcutaneous injection), inhalation (e.g., intra

ocular angiogenesis. One or more inhibitors of CCR3 recep
tor function, such as those identi?ed as described herein, can

bronchial, intranasal or oral inhalation, intranasal drops), and
intraocular injection routes of administration, depending on

be used to inhibit ocular angiogenesis for therapeutic pur
poses.

the disease or condition to be treated. Intraocular injection

Thus, the present invention provides a method of inhibiting
ocular angiogenesis in an individual in need of such therapy,
comprising administering a compound Which inhibits mam

routes include periocular (subconjunctival/transscleral),
intravitreous, subretinal, suprachoroidal and intracameral
modes of injection.

malian CCR3 receptor function to an individual in need of

Formulation of a compound to be administered Will vary

such therapy. Such individuals include those having age
related macular degeneration.
The present inventors have found that CCR3 is highly
expressed by endothelial cells of choroidal neovasculariZa
tion membrane in patients With Wet age-related macular
degeneration. Thus, in one aspect of the invention, CCR3
expression is used as a target for diagnosis or therapy of
choroidal neovasculariZation or Wet age-related macular

according to the route of administration selected (e.g., solu

tion, emulsion, capsule). An appropriate composition com

20

prising the compound to be administered can be prepared in a
physiologically acceptable vehicle or carrier. For solutions or
emulsions, suitable carriers include, for example, aqueous or
alcoholic/ aqueous solutions, emulsions or suspensions,
including saline and buffered media. Parenteral vehicles can

include sodium chloride solution, Ringer’s dextrose, dextrose

degeneration. For diagnosis of choroidal neovasculariZation

and sodium chloride, lactated Ringer’s or ?xed oils. Intrave

or Wet macular degeneration, a molecule Which can speci?

nous vehicles can include various additives, preservatives, or

cally bind CCR3 or any portion thereof (e.g., an antibody) is
administered to the patient. A reporter group is attached to the

25

?uid, nutrient or electrolyte replenishers (See, generally,
Remington’s Pharmaceutical Science, 16th Edition, Mack,

CCR3-speci?c binding molecule so that in situ expression of

Ed. 1980). For inhalation, the compound is solubiliZed and

CCR3 can be monitored. Appropriate reporter groups include

loaded into a suitable dispenser for administration (e.g., an

?uorescent dyes, radionuclides, and dense metal particles,

atomiZer, nebuliZer or pressuriZed aerosol dispenser). As

although any appropriate detectable reporter group can be
used. An abundance of CCR3-speci?c binding molecule

30

detected in the retina or choroid Would be indicative of cho

roidal neovascularization or Wet macular degeneration. Early

sclera, in the suprachoroidal space, or in the subretinal space.
In another embodiment, the present invention provides
methods for screening compounds that interact With CCR3.

detection of CCR3 overexpression in the retina or choroid

before overt signs of macular degeneration develop alloWs for
therapy to be initiated early, even before choroidal neovascu

lariZation takes place, thereby leading to more effective treat
ment of the disease. In addition, administration of the labeled
CCR3-speci?c binding molecule can be used to monitor the
progress of any therapy.
Administration of CCR3-speci?c binding molecule can

35

solution, a?ixed to a solid support, borne on a cell surface or
40

located intracellularly. One method of drug screening utiliZes
eukaryotic or prokaryotic host cells Which are stably trans
formed With recombinant nucleic acids expressing the

also be used as a Way of treating choroidal neovasculariZation

molecule can act directly by removing CCR3, thereby stop

polypeptide or fragment. Drugs are screened against such
transformed cells in competitive binding assays. Such cells,

ping or reducing neovasculariZation. In another aspect, the
45

either in viable or ?xed form, can be used for standard binding
assays. One may measure, for example, the formation of

complexes betWeen CCR3 and the agent being tested. Alter

speci?c binding molecule can be administered to the patient

natively, one can examine the diminution in complex forma
tion betWeen CCR3 and its target cell, monocyte, etc. caused

in conjunction With, or folloWed by, administration of a sec

ond molecule Which speci?cally binds the CCR3-speci?c
binding molecule. A toxin, radionuclide or other entity Which

The present invention is useful for screening compounds by
using CCR3 polypeptide or binding fragments thereof in any
of a variety of drug screening techniques. The CCR3 polypep
tide or fragment employed in such a test may either be free in

or Wet macular degeneration. The CCR3-speci?c binding
CCR3-speci?c binding molecule can have attached to it a
toxin, radionuclide or other entity Which kills or inhibits the
cells involved in neovasculariZation. Alternatively, a CCR3

another example, a compound may be administered via a
sustained release device or composition Which is implanted in
the vitreous humor, aqueous humor, on the sclera, in the

50

by the agent being tested.
Thus, the present invention provides methods of screening

kills or inhibits the cells involved in neovasculariZation is

for drugs or any other agents Which can affect ocular angio

attached to the second molecule, thereby providing for treat

genesis and disease. These methods comprise contacting such

ment of choroidal neovasculariZation or Wet macular degen
eration.
The methods of the present invention can be used in any

an agent With a CCR3 polypeptide or fragment thereof and
55

mammalian species, including human, monkey, coW, sheep,
pig, goat, horse, mouse, rat, dog, cat, rabbit, guinea pig,

ence of a complex betWeen the CCR3 polypeptide or frag
ment and the cell, by methods Well knoWn in the art. In such

competitive binding assays, the CCR3 polypeptide or frag

hamster and horse. Humans are preferred.
According to the method of the invention, one or more

60

compounds can be administered to the host by an appropriate
route, either alone or in combination With another drug. An
effective amount of a compound (e.g., a small molecule

ment is typically labeled. After suitable incubation, free
CCR3 polypeptide or fragment is separated from that present
in bound form, and the amount of free or uncomplexed label
is a measure of the ability of the particular agent to bind to
CCR3 or to interfere With the CCR3 and agent complex.

CCR3 receptor antagonist Which inhibits ligand binding, an
antibody or an siRNA) is administered. An effective amount
is an amount su?icient to achieve the desired therapeutic
effect, under the conditions of administration, such as an

assaying (i) for the presence of a complex betWeen the agent
and the CCR3 polypeptide or fragment, or (ii) for the pres

65

Another technique for drug screening provides high
throughput screening for compounds having suitable binding
a?inity to the CCR3 polypeptide and is described in detail in
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European PatentApplication 84/ 03564, published on Sep. 13,

treatment Were incubated in Fc block (0.5 mg/ml; BD Pharm
ingen) for 15 min on ice. Rat antibody to mouse CCR3

1984, incorporated herein by reference. Brie?y stated, large
thesiZed on a solid substrate, such as plastic pins or some

(1:250; Santa CruZ) coupled With PE-donkey antibody to rat
lgG (1:250; Jackson lmmunoresearch) Were used to quantify

other surface. The peptide test compounds are reacted With

cell surface receptor expression on choroidal endothelial

CCR3 polypeptide and Washed. Bound CCR3 polypeptide is
then detected by methods Well knoWn in the art. Puri?ed

cells, de?ned by CD31"VEGFR-2+ expression, gated by

CCR3 can also be coated directly onto plates for use in the

numbers of different small peptide test compounds are syn

FlTC-conjugated rat antibody to mouse CD31 (1:250; BD

aforementioned drug screening techniques. In addition, non

Biosciences) and PerCP-Cy5.5-conjugated rat antibody to
mouse CD11b (1:50; BDBiosciences). Macrophages, neutro

neutraliZing antibodies can be used to capture the peptide and

phils, eosinophils and mast cells Were de?ned as 134/80+

immobiliZe it on the solid support.

CD11c‘, Gr-1+F4/80_, CCR3’"CD3‘CD117””CD49d+ and
CCR3i”’CD3_CD117hiCD49d+ cells, respectively. DNA

This invention also contemplates the use of competitive

drug screening assays in Which neutraliZing antibodies

content for cell cycle Was analyZed after incubation With

capable of binding CCR3 speci?cally compete With a test
compound for binding to CCR3 polypeptides or fragments

propidium iodide (0.05 mg/ml; Molecular Probes) containing
0.1% Triton X-100 and RNase A (0.1 mg/ml; Roche).
Because the probability of each laser lesion developing
CNV is in?uenced by the group to Which it belongs, the

thereof In this manner, the antibodies can be used to detect the
presence of any peptide Which shares one or more antigenic
determinants With CCR3.

The present invention also contemplates the use of drug
screening assays in Which drugs or any other agents are moni

mouse, the eye, and the laser spot, the mean lesion volumes
20

tored in a bioassay, such as the ability of the drug or agent to

inhibit ocular angiogenesis. Such a drug screening assay may
be used in conjunction With the various binding assays
described above, i.e., drugs or other agents may be ?rst tested
for their ability to bind to CCR3, and those compounds hav
ing binding af?nity for CCR3 are then tested in a bioassay,

mined at the 0.05 level. Post hoc comparison of means Was
constructed With a Bonferroni adjustment for multiple com
25

angiogenesis. Alternatively, the bioassay may be conducted
30

CCR3. Inhibition of ocular angiogenesis With the drug or
agent but no inhibition of ocular angiogenesis With drug or
agent in the presence of a compound Which blocks the action
of CCR3 Would be indicative of a compound that inhibits

ocular angiogenesis by interacting With CCR3. Similar
screening assays can be performed comparing ocular angio
genesis in Wild-type cells versus cells in Which the genes for
CCR3 are knocked out, With inhibition of ocular angio genesis
in Wild-type cells due to exposure to drug agent and no inhi
bition in the knockout cells being indicative of the drug or

parisons.
Results
As illustrated by FIG. 1, the number of CCR3 receptors on

such as the ability of the drug or agent to inhibit ocular
With the drug or agent With or Without a compound Which
blocks the action of CCR3, such as an antibody against

Were compared using a linear mixed model With a split plot
repeated measures design. The Whole plot factor Was the
genetic group to Which the animal belonged While the split
plot factor Was the eye. Statistical signi?cance Was deter

choroidal endothelial cells in vivo folloWing laser injury (red)
is signi?cantly greater than the number before injury (green),
indicating upregulation of CCR3 receptors on these cells.
Eosinophils or mast cells are the principal cells in most sys

tems that respond to CCR3. HoWever, the number of eosino
phils and mast cells in the choroid Was unaffected by injury or
CCR3 Ab (FIG. 4). CCR3 Ab did not inhibit choroidal mac
35
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agent inhibiting ocular angiogenesis by interacting With

rophage in?ltration folloWing injury (FIG. 5), indicating that
laser injury is not Working by anti-in?ammatory means. As
illustrated by FIG. 3, CCR3 Ab suppressed CNV volume in
C57BL/6] mice by nearly 60% in a dose-dependent and sta
tistically signi?cant manner compared to vehicle control
(PBS) and control antibody (rat lgG2a). FIG. 2 demonstrates
that CCR3 Ab blockade, but not control antibody (rat lgG2a),

inhibited proliferation (S phase) of CECs (choroidal endot
helial cells) in vivo folloWing laser injury. Experiments in

CCR3.

Example 1
45

Methods

Ccr3 —/— mice con?rmed these results. Of the CCR3 ligands,
blockade of only eotaxin (45%) or eotaxin-2 (70%) sup
pressed CNV in C57BL/6] mice compared to control anti

bodies (all Ps<0.001). Experiments in Cc111—/— and
Laser photocoagulation (532 nm, 200 mW, 100 ms, 75 um)

(OcuLight GL, lridex Corporation) Was performed (volume
studies: 3/eye; protein analyses/?ow cytometry: 12/eye) on

Cc124—/— mice con?rmed these results.
50

These ?ndings demonstrate that CCR3 receptor promotes
angiogenesis not via leukocyte modulation but rather by

both eyes of each animal to induce CNV (choroidal neovas

direct effects on CECs. Thus, CCL-11, CCL-24, and CCR3

culariZation). CNV volumes Were measured by scanning
laser confocal microscope (TCS SP, Leica) With 0.5% FITC

degeneration).

are neW targets for neovascular AMD (age-related macular

Grz?‘onia simplicifolia lsolectin B4 (Vector Laboratories).
CNV Was induced by laser injury in C57BL/6] and Ccr3_/_
mice and volumes measured 7 days later by confocal evalu
ation of Grifonia simplicifolia lsolectin B4 staining of RPE

Methods

choroid ?atmounts. Neutralizing antibodies (Ab) against
CCR3, eotaxin (CCL-11), eotaxin-2 (CCL-24), RANTES,
MCP-3 or control goat IgG or rat lgG2a Were injected into the

Male C57BL/6J mice (Jackson Laboratories) betWeen 6
60

vitreous humor folloWing injury.

and 8 Weeks of age Were used to minimiZe variability. For all

procedures, anesthesia Was achieved by intraperitoneal inj ec

tion of 50 mg/kg ketamine hydrochloride (Ft. Dodge Animal
Health) and 10 mg/kg xylaZine (Phoenix Scienti?c), and
pupils Were dilated With topical 1% tropicamide (Alcon

FloW cytometry Was used to determine the numbers of

eosinophils, mast cells and macrophages in the choroid,
expression of CCR3 by various cell types in the eye, and the
cell cycle state of choroidal endothelial cells (CECs) in vivo.
Suspensions of cells isolated from mouse RPE/choroid by
incubation With collagenase D (20 U/ml; Roche Diagnostics)

Example 2

55

65

Laboratories).
Laser photocoagulation (532 nm, 200 mW, 100 ms, 75 um)

(OcuLight GL, lridex Corporation) Was performed (volume
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studies: 3/eye; protein analyses/?oW cytometry: 12/eye) on

2). Eotaxin-1 and -3 also induced a second delayed burst of
F-actin polymerization betWeen 30 and 60 seconds. PBS
controls resulted in no signi?cant increase in F-actin poly
merization from baseline.

both eyes of each animal to induce CNV. CNV volumes Were

measured by scanning laser confocal microscope (TCS SP,
Leica) With 0.5% FlTC-Grz?bnia simplicifolia lsolectin B4
(Vector Laboratories) or 0.5% FlTC-rat antibody against
mouse CD31 (BD Biosciences). Volumes obtained by lectin

As shoWn in FIG. 10, ?uorescent microscopic images
shoWed minimal ?uorescence in untreated baseline cultures
that Were approximately 70-80% con?uent. After 10 seconds
of eotaxin stimulation, hCEC cultures exhibited increased
?uorescence and cord characteristic of F-actin polymeriza
tion.

and CD31 staining Were highly correlated (r2:0.95). (S)

Methyl-2-naphthoylamino-3-(4-nitrophenyl)propionate
(SB328437; Calbiochem) dissolved in DMSO Was injected
into the vitreous humor of Wild-type mice using a 33-gauge

double-caliber needle (Ito Corporation) immediately after
laser injury.

Example 4

Suspensions of cells isolated from mouse RPE/choroid by

incubation With collagenase D (20 U/ml; Roche Diagnostics)

A Rac-1 activation assay Was performed. Human CECs
Were cultured in EGM-2 MV containing 5% FBS. Prior to
starting the assay, cells Were serum starved With basal

treatment Were incubated in Fc block (0.5 mg/ml; BD Pharm
ingen) for 15 min on ice. Rat antibody to mouse CCR3

(1:250; Santa Cruz) coupled With PE-donkey antibody to rat
lgG (1:250; Jackson lmmunoresearch) Were used to quantify

medium (MCDB131) supplemented With 1% FBS overnight.
Cells Were stimulated for designated times With Eotaxin-1, 2

cell surface receptor expression on choroidal endothelial

cells, de?ned by CD31"VEGFR-2+ expression. DNA content
for cell cycle Was analyzed after incubation With propidium

20

PBD agarose beads (Upstate) to pull-doWn active GTP-bound

iodide (0.05 mg/ml; Molecular Probes) containing 0.1% Tri

Rac-1 at 40 C. for 1 hour With rotation. The samples Were

ton X-100 and RNase A (0.1 mg/ml; Roche). Paraf?n embed
ded sections of human eyes or CNV membranes Were stained

With antibodies against human CCR3 or human vWF and

and 3 (10 ng/ml, 100 ng/ml and 2 ug/ml respectively). Equal
amounts of lysates (500 pg) Were incubated With GST-Pakl -

25

identi?ed With Cy2 or Cy3 secondary antibodies.

subsequently analyzed for bound Rac-1 by Western blot
analysis using an anti-Rac-1 antibody (Upstate). Band den
sity Was measured using VisionWorksLS softWare (UVP).
hCECs) Were stimulated With Eotaxin-1, 2 and 3 for indi

Results

As illustrated by FIG. 6, folloWing laser injury there is a
signi?cantly greater number of CCR3 receptors in vivo on
proliferating mouse choroidal endothelial cells (S+G2/M cell

cated times. Cells Without Eotaxin stimulation Were used as a
30

doWn assays. Levels of increase of active Rac-1 Were mea

cycle phase; light curve) than the number on quiescent cells
(G0/ G1 phases; dark curve). The results indicate that there is

sured after normalizing against the control band density. As
shoWn in FIG. 11B, eotaxins activated Rac-1 GTPase in
Human CECs (hCECs). Eotaxin-1 stimulation shoWed about

upregulation of CCR3 receptors on the proliferating cells.
FIG. 7 shoWs that the CCR3 small molecule antagonist

SB328437 ((S)-methyl-2-naphthoylamino-3-(4-nitrophenyl)

35

propionate) reduces CNV volume in a dose-dependent and
statistically signi?cant manner compared to vehicle control

cells of a CNV membrane excised from a patient With AMD,
both on endothelial cells and in the stroma.

6.5 fold increase of Rac-1 activation at 10 seconds. Eotaxin-2
and Eotaxin-3 stimulation shoWed 3 to 5 fold increase of
Rac-1 activation peaking at 60 seconds.

All references cited in this disclosure are incorporated by

(DMSO). In FIG. 8(A), immunohistochemistry shoWs that
CCR3 is expressed in the neural retina of patients Without
age-related macular degeneration (AMD) but not in the chor
oid. In FIG. 8(B), CCR3 expression is reduced in the retina
and absent in the choroid of patients With AMD Who have
drusen but not choroidal neovascularization (CNV). FIG.
8(C) shoWs that CCR3 is highly expressed in the endothelial

control (0 sec). Equal amount (500 pg) of total cell lysates Was
used to determine the GTP-bound Rac-1 (active) by pull

reference to the same extent as if each reference had been
40

incorporated by reference in its entirety individually.
While the invention has been described in detail and With

reference to speci?c embodiments thereof, it Will be apparent
to one skilled in the art that various variations and modi?ca

tions can be made therein Without departing from the sprit and
45

scope thereof. All such variations and modi?cations are
intended to be includedWithin the scope of this disclosure and

the present invention and protected by the folloWing claims.

Example 3
A F-actin polymerization assay Was performed. 10,000
cells from early passage primary hCEC isolates (n:3) Were
seeded in black-Walled 96-Well plates and groWn to 70-80%
con?uency in fully supplemented EGM-2MV. Cultures Were

50

Wet macular degeneration, comprising administering an
effective amount of a CCR3-speci?c binding molecule to a

patient having choroidal neovascularization or Wet macular
degeneration Wherein the speci?c binding molecule is a small

serum starved overnight in basal media and then stimulated

With recombinant human eotaxin-1 (10 ng/mL), eotaxin-2

I claim:
1. A method of treating choroidal neovascularization or

55

(100 ng/mL), eotaxin-3 (2 ug/mL) (Peprotech), or vehicle

organic molecule.
2. The method of claim 1 Wherein the CCR3-speci?c bind

ing molecule is orally administered to the patient.

control (PBS). At 0, 10, 30, 60, or 120 second time-points
(n:4 per group), cells Were ?xed in 3.7% paraformaldehyde
for 10 minutes, Washed, permeabilized in PBS With 0.1%

3. The method of claim 1 Wherein the CCR3-speci?c bind

ing molecule is intravenously administered to the patient.
4. The method of claim 1 Wherein the CCR3-speci?c bind

Triton-X, and then stained With rhodamine labeled Phalloidin

(1:200, lnvitrogen) per manufacturer’s recommendations.

ing molecule is intraocularly injected into the patient.

Plates Were analyzed on a ?uorescent plate reader (Synergy 4,

5. The method of claim 1 Wherein the CCR3-speci?c bind
ing molecule is topically administered to the patient via eye

Biotek) folloWed by ?uorescent microscopy (Nikon E800).

drops.

F-actin polymer ratios betWeen baseline and treated cul
tures Were calculated using a ?uorescent based plate assay. As

seen in FIG. 9, polymerization peaked at 10 seconds after
stimulation With all eotaxins (eotaxin-1>eotaxin-3>eotaxin

65

6. The method of claim 1 Wherein the CCR3-speci?c bind
ing molecule is an organic molecule With a molecular Weight
less than 2000.

US 8,592,482 B2
13
7. The method of claim 1 wherein the CCR3-speci?c bind
ing molecule is an organic molecule With a molecular Weight
less than 1000.
8. The method of claim 1 Wherein the CCR3-speci?c bind
ing molecule is an organic molecule With a molecular Weight
less than 500.
9. The method of claim 1 Wherein the CCR3-speci?c bind

ing molecule is (S)-methyl-2-naphthoylamino-3-(4-nitro

phenyl)propionate.
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